ADMA Biologics (ADMA +48%) is up on almost a 5x surge in volume. Shares have rallied almost 128% since touching $1.45 on March 18.
Investors appear bullish on the company’s hyperimmune Asceniv (immune globulin intravenous, human – sira) 10% liquid, approved by
the FDA about a year ago for the treatment of primary humoral
immunodeficiency disease, for the potential treatment of COVID-19.
During the company’s Q4 earnings call on March 12,
CEO Adam Grossman said that, although it would take 7-12 months to
produce a batch from COVID-19 survivors, Asceniv has high titers of
antibodies to a coronavirus called HCoV-OC43 which
cross-reacts with SARS-CoV-2, adding that it is doing its best to “gain
attention” from U.S. health authorities on its potential use in the
current outbreak.
https://seekingalpha.com/news/3554305-adma-biologics-adds-to-coronavirus-stocked-rally-up-48
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.